ADAM17 Protein

A disintegrin and metalloproteinase domain-containing protein that cleaves the membrane-bound precursor of TUMOR NECROSIS FACTOR-ALPHA to its mature form. It cleaves several other CELL SURFACE PROTEINS, including INTERLEUKIN-1 RECEPTOR TYPE II; TRANSFORMING GROWTH FACTOR ALPHA; L-SELECTIN; MUCIN-1; and AMYLOID BETA-PROTEIN PRECURSOR. It can also function as an activator of the Notch signaling pathway by mediating the cleavage of NOTCH RECEPTORS.

Also Known As:

ADAM-17; ADAM-17 Protein; CD156b Antigen; Disintegrin and Metalloproteinase Domain-Containing Protein 17; TACA (Enzyme); TACE (Enzyme); TNF-alpha Convertase; TNF-alpha Converting Enzyme; Tumor Necrosis Factor Alpha Convertase; Tumor Necrosis Factor-alpha Convertase; Tumor Necrosis Factor-alpha Converting Enzyme; ADAM 17 Protein; Antigen, CD156b; Convertase, TNF-alpha; Disintegrin and Metalloproteinase Domain Containing Protein 17; TNF alpha Convertase; TNF alpha Converting Enzyme; Tumor Necrosis Factor alpha Converting Enzyme

Networked: 202 relevant articles (4 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rose-John, Stefan: 4 articles (01/2021 - 07/2014)
2.	Federici, Massimo: 4 articles (01/2010 - 12/2005)
3.	Lauro, Renato: 4 articles (01/2010 - 12/2005)
4.	Menghini, Rossella: 4 articles (01/2010 - 12/2005)
5.	Levin, J I: 4 articles (03/2006 - 10/2001)
6.	Furuya, Hidekazu: 3 articles (04/2018 - 01/2018)
7.	Ishii, Sho: 3 articles (04/2018 - 01/2018)
8.	Isozaki, Takeo: 3 articles (04/2018 - 01/2018)
9.	Kasama, Tsuyoshi: 3 articles (04/2018 - 01/2018)
10.	Crown, J: 3 articles (06/2015 - 06/2008)

Related Diseases

1.	Ischemia 09/01/2009 - "Preconditioning with sublethal ischemia or intermittent normobaric hyperoxia up-regulates glutamate transporters and tumor necrosis factor-alpha converting enzyme in the rat brain." 04/01/2004 - "DPH-067517 selectively inhibited TACE enzyme activity in vitro (K(i) = 2.8 nM), and effectively suppressed ischemia-induced increase in soluble TNFalpha in brain tissue after systemic administration. " 08/01/2009 - "To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis. " 09/24/2007 - "Here, we assessed the effects of PKF242-484 and PKF241-466, two dual inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases (MMPs), in a model of ischemia and reperfusion injury in mice. " 12/01/2008 - "In isolated ventilated (by air containing 5% CO(2)) rat lungs, in which differential perfusion of the RL or LL was feasible, the LL was selectively made ischemic (60 min) and reperfused (30 min) in a nonrecirculating or recirculating manner with buffer (Krebs-Henseleit) solution, or in a recirculating manner with buffer that contained apocynin (10 mmol/L) or apocynin + TACEI (tumor necrosis factor)-alpha converting enzyme inhibitor; 10 microg/mL) (each group: n = 12) or with buffer that contained SOD (superoxide dismutase, 3000 U before ischemia and at reperfusion) or SOD + TACEI (each group: n = 5). "
2.	Reperfusion Injury 12/15/2006 - "TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats." 09/24/2007 - "Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice." 09/24/2007 - "Here, we assessed the effects of PKF242-484 and PKF241-466, two dual inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases (MMPs), in a model of ischemia and reperfusion injury in mice. "
3.	Polycystic Kidney Diseases (Polycystic Kidney Disease) 10/01/2001 - "A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease." 05/01/2005 - "Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease."
4.	Chronic Renal Insufficiency 07/01/2010 - "This work presents preliminary evidence that 1,25(OH)2D inhibition of TACE (Tumor necrosis factor Alpha Converting Enzyme) is a potential common mechanism underlying the efficacy of therapy with 1,25(OH)2D or its analogs to improve outcomes in chronic kidney disease. "
5.	Retinal Neovascularization 08/01/2009 - "CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo." 08/01/2009 - "To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Tissue Inhibitor of Metalloproteinase-3
3.	Matrix Metalloproteinases (MMPs)
4.	3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amide
5.	hydroxide ion
6.	ADAM17 Protein
7.	Metalloproteases (Metalloproteinases)
8.	Disintegrins
9.	Enzymes
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)